Logo

Zenas Acquires Exclusive WW Rights of Xencor's obexelimab for the Treatment of Autoimmune Diseases

Share this

M&A

Zenas Acquires Exclusive WW Rights of Xencor's obexelimab for the Treatment of Autoimmune Diseases

Shots:

  • Xencor gets the right to acquire additional Zenas equity & is also eligible to receive ~$480M upon achievement of clinical development, regulatory & commercialization milestones along with royalties of obexelimab
  • Zenas get an exclusive global right to develop, manufacture & commercialize obexelimab & will be responsible to advance the research, development, regulatory & commercial activities of obexelimab globally
  • The acquisition will bolster Zenas’s pipeline with the addition of obexelimab in its portfolio for autoimmune diseases. Obexelimab is a bifunctional Abs that targets CD19 with its variable domain and uses Xencor's XmAb immune inhibitor Fc domain to target FcγRIIb

Ref:Xencor | Image: Xencor


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions